Deciphera Pharmaceuticals, Llc

This early-stage study is testing a new drug called DCC-3116, both by itself and combined with other cancer drugs, for people with advanced solid tumors that have specific genetic changes. The main goals are to find safe doses and see if the treatments can shrink tumors. It is fo…

This study is testing an experimental drug called vimseltinib in adults with advanced solid tumors or a rare joint tumor called tenosynovial giant cell tumor (TGCT). The first phase aims to find the safest and most effective dose. The second phase will focus on TGCT patients to s…

This study is testing whether an experimental drug called vimseltinib can shrink tumors in people with tenosynovial giant cell tumor (TGCT) when surgical removal isn't an option. About 123 adults with symptomatic TGCT will receive either vimseltinib or a placebo for 24 weeks, wit…

This study compares two drugs, ripretinib and sunitinib, for patients with advanced gastrointestinal stromal tumor (GIST) whose cancer has grown despite initial treatment with imatinib. It specifically targets patients whose tumors have certain genetic mutations. The goal is to s…

This study compares two drugs, ripretinib and sunitinib, for patients with advanced gastrointestinal stromal tumors (GIST) whose cancer has worsened or who couldn't tolerate the standard first treatment, imatinib. About 453 patients worldwide will take one of the two drugs daily …